Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 2
2010 5
2011 5
2012 6
2013 5
2014 6
2015 4
2016 4
2017 4
2018 7
2019 8
2020 4
2021 3
2022 3
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

60 results

Results by year

Filters applied: . Clear all
Page 1
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.
von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N, Clark E, Knott A, Lang I, Levy C, Yardley DA, Bines J, Gelber RD, Piccart M, Baselga J; APHINITY Steering Committee and Investigators. von Minckwitz G, et al. N Engl J Med. 2017 Jul 13;377(2):122-131. doi: 10.1056/NEJMoa1703643. Epub 2017 Jun 5. N Engl J Med. 2017. PMID: 28581356 Free PMC article. Clinical Trial.
Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial.
Pérez-García JM, Vaz Batista M, Cortez P, Ruiz-Borrego M, Cejalvo JM, de la Haba-Rodriguez J, Garrigós L, Racca F, Servitja S, Blanch S, Gion M, Nave M, Fernández-Abad M, Martinez-Bueno A, Llombart-Cussac A, Sampayo-Cordero M, Malfettone A, Cortés J, Braga S. Pérez-García JM, et al. Among authors: servitja s. Neuro Oncol. 2023 Jan 5;25(1):157-166. doi: 10.1093/neuonc/noac144. Neuro Oncol. 2023. PMID: 35639825 Free PMC article. Clinical Trial.
LCOR mediates interferon-independent tumor immunogenicity and responsiveness to immune-checkpoint blockade in triple-negative breast cancer.
Pérez-Núñez I, Rozalén C, Palomeque JÁ, Sangrador I, Dalmau M, Comerma L, Hernández-Prat A, Casadevall D, Menendez S, Liu DD, Shen M, Berenguer J, Ruiz IR, Peña R, Montañés JC, Albà MM, Bonnin S, Ponomarenko J, Gomis RR, Cejalvo JM, Servitja S, Marzese DM, Morey L, Voorwerk L, Arribas J, Bermejo B, Kok M, Pusztai L, Kang Y, Albanell J, Celià-Terrassa T. Pérez-Núñez I, et al. Among authors: servitja s. Nat Cancer. 2022 Mar;3(3):355-370. doi: 10.1038/s43018-022-00339-4. Epub 2022 Mar 17. Nat Cancer. 2022. PMID: 35301507
Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor-Positive, ERBB2-Negative Advanced Breast Cancer: A Randomized Clinical Trial.
Llombart-Cussac A, Pérez-García JM, Bellet M, Dalenc F, Gil-Gil M, Ruíz-Borrego M, Gavilá J, Sampayo-Cordero M, Aguirre E, Schmid P, Marmé F, Di Cosimo S, Gligorov J, Schneeweiss A, Albanell J, Zamora P, Wheatley D, Martínez-de Dueñas E, Amillano K, Malfettone A, Cortés J; PARSIFAL Steering Committee and Trial Investigators. Llombart-Cussac A, et al. JAMA Oncol. 2021 Dec 1;7(12):1791-1799. doi: 10.1001/jamaoncol.2021.4301. JAMA Oncol. 2021. PMID: 34617955 Free PMC article. Clinical Trial.
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.
Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Medeiros Alencar VH, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou MF, Inbar M, Khaled H, Kielanowska J, Kwan WH, Mathew BS, Mittra I, Müller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, Radhika R, Rajan B, Rubach MT, Tort S, Urrútia G, Valentini M, Wang Y, Peto R; Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group. Davies C, et al. Lancet. 2013 Mar 9;381(9869):805-16. doi: 10.1016/S0140-6736(12)61963-1. Lancet. 2013. PMID: 23219286 Free PMC article. Clinical Trial.
Long-term outcomes of high-risk HR-positive and HER2-negative early breast cancer patients from GEICAM adjuvant studies and El Álamo IV registry.
Martín M, Carrasco E, Rodríguez-Lescure Á, Andrés R, Servitja S, Antón A, Ruiz-Borrego M, Bermejo B, Guerrero Á, Ramos M, Santaballa A, Muñoz M, Cruz J, Lopez-Tarruella S, Chacón JI, Álvarez I, Martínez P, Miralles JJ, Polonio Ó, Jara C, Aguiar-Bujanda D. Martín M, et al. Among authors: servitja s. Breast Cancer Res Treat. 2023 Sep;201(2):151-159. doi: 10.1007/s10549-023-07002-1. Epub 2023 Jun 20. Breast Cancer Res Treat. 2023. PMID: 37338729 Free PMC article. Review.
Dual neoadjuvant blockade plus chemotherapy versus monotherapy for the treatment of women with non-metastatic HER2-positive breast cancer: a systematic review and meta-analysis.
Vazquez JC, Antolin S, Ruiz-Borrego M, Servitja S, Alba E, Barnadas A, Lluch A, Martin M, Rodriguez-Lescure A, Sola I, Bonfill X, Urrutia G, Sanchez-Rovira P. Vazquez JC, et al. Among authors: servitja s. Clin Transl Oncol. 2023 Apr;25(4):941-958. doi: 10.1007/s12094-022-02998-2. Epub 2022 Nov 22. Clin Transl Oncol. 2023. PMID: 36417083 Review.
Chemotherapy-induced nausea and vomiting: pathophysiology and therapeutic principles.
Bayo J, Fonseca PJ, Hernando S, Servitja S, Calvo A, Falagan S, García E, González I, de Miguel MJ, Pérez Q, Milena A, Ruiz A, Barnadas A. Bayo J, et al. Among authors: servitja s. Clin Transl Oncol. 2012 Jun;14(6):413-22. doi: 10.1007/s12094-012-0818-y. Clin Transl Oncol. 2012. PMID: 22634529 Review.
60 results